Molecular Prognostic Prediction By Support Vector Machine Integrated Approach For Local Advanced Nasopharyngeal Carcinoma.
Xiang-Bo Wan,X. Wu,X. Fan,H. Cai,Ming Yuan Chen,Jie Xu,Ming Huang Hong,Quentin Liu
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.5514
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:5514 Background: Accurate means to refine the prognosis of local advanced nasopharyngeal carcinoma (NPC) will improve the selection of patients for tailored therapy. Here, we addressed this issue by developing a mathematical algorithm, Support Vector Machine (SVM), by integrating pathological multibiomarkers. Methods: Ninety-seven local advanced NPC patients (stage III and IVa) in a randomized controlled trial (RCT), consisting of 48 cases serving as the training set and 49 cases as testing set of SVM models, with a 5-year follow-up were selected and studied. We designed 3 SVM models by selecting the variables from 38 tissue molecular biomarkers and 3 EBV related serological biomarkers. Results: The SVM1 displayed highly prognostic sensitivity (sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 88.0%, 81.9%, 62.9%, 95.2% and 83.5%, respectively) by integrating 7 molecular biomarkers (Aurora-A, Beclin 1, Ki-67, N-cadherin, nm23-H1, P27, and TIMP 2). The SVM2 model showed highly prognostic specificity (sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 84.0%, 94.5%, 84.0%, 94.4% and 91.8%, respectively) by grouping 12 molecular biomarkers (nm23-H1, Pontin, cyclin D1, N-Cadherin, 14-3-3s, Ki-67, Aurora-A, Bcl-2, Beclin 1, MMP 2, EZH2 and TIMP 2) and 3 EBV related serological biomarkers (EA-IgA, VCA-IgA and AER). The SVM3 model, constructed by combination SVM1 with SVM2, displayed a high prognostic capacity (sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy were 88.0%, 90.3%, 75.9%, 95.6% and 89.7%, respectively). Moreover, Cox multivariate regression analysis confirmed that these 3 SVM models were each the significant independent prognostic model (SVM1, HR: 70.745, P = 0.000; SVM2, HR: 145.080, P = 0.000; SVM3, HR: 113.594, P = 0.000) for overall survival in testing set and overall patients. Conclusions: Our SVM prognostic models designed in the RCT displayed strong power in refining patient prognosis for local advanced NPC, potentially directing future target therapy against the correlated signaling pathways.